Q: Dear Pat: Johnson & Johnson seems to be a widely recommended stock. Please, may I have your analysis?

Mar 13 18:03 2018 Print This Article

A: Johnson & Johnson, $135.11, symbol JNJ on New York (Shares outstanding: 2.7 billion; Market cap: $364.8 billion; www.jnj.com), operates through three major businesses: Pharmaceutical (47% of revenue) makes anti-infective, antipsychotic, contraceptive, dermatological and gastrointestinal drugs; Medical devices and diagnostics (35%) sells equipment for joint reconstruction and managing circulatory diseases; Consumer (18%) makes over-the-counter products […]

The post Q: Dear Pat: Johnson & Johnson seems to be a widely recommended stock. Please, may I have your analysis? appeared first on TSI Wealth Network.

Read More

About Article Author

TSI Network Daily

TSI Network is the online home of Pat McKeough’s highly successful family of investment publications, TSI The Successful Investor, TSI Stock Pickers Digest, TSI Wall Street Stock Forecaster and TSI Canadian Wealth Advisor. While most media outlets only cover the popular investment theories of the day, TSI Network goes beyond the headlines to get to the heart of what really affects you – the individual investor. The site is based on Pat’s rock-solid investing system and his unflinching focus on helping North American investors make the right choices for their own unique investment needs. A professional investment analyst for more than 25 years, Pat has developed a stock-selection technique that has proven reliable in both bull and bear markets. His proprietary ValuVesting System™ focuses on stocks that provide exceptional quality at relatively low prices. Many savvy investors and industry leaders consider it the most powerful stock-picking method ever createdAs early as 1980, Pat was recognized as #1 in the world of published investment advice by the Washington, DC–based Newsletter Publishers Association, and he was the first multi-year winner of The Globe and Mail‘s stock picking contest. Both CBS MarketWatch and The Hulbert Financial Digest recognize Pat as one of North America’s top stock analysts. The Wall Street Journal calls him “one of only four investment newsletter advisors who have managed to serve their readers well over the long haul.”

  Categories:

Related Items

US Business Cycle Risk Report | 20 September 2018

US economic growth remains strong, based on data published to date, but today’s business-cycle profile continues to suggest that we’ve seen the peak. Recession risk remains low and near-term projections point to more of the same. The question is whether there’s trouble brewing for 2019? At th ...

Macro Briefing: 20 September 2018

US prepared to resume denuclearization talks with North Korea: ReutersPolls continue to give Dems edge for taking back House in Nov: RCPChina set to cut average trade tariffs for most of its partners: BloombergWill China retaliate in trade war by selling its massive Treasury holdings? NY PostThe pa ...

Panoramic Weekly: Ignoring Trump

Most global fixed income asset classes gained over the past five trading days, despite an escalation of the ongoing US-China trade war and the inclusion of new tariffs between the world’s two largest economies. Reduced trade, however, may bring more harm than good to the US economy, as levies usu ...

More than a year later, how has Mexican natural gas pricing evolved?

In June 2017, Mexico’s Energy Regulatory Commission (CRE) announced the elimination of the maximum price of natural gas, known as the first-hand price, or the VPM. Instead of using this price cap formula, the state-owned oil and natural gas company, Petroleos Mexicanos (Pemex), alongside independ ...

Indian pharmaceutical patent prosecution: The changing role of Section 3(d)

This article was originally published at https://www.drugpatentwatch.com/blog/indian-pharmaceutical-patent-prosecution-the-changing-role-of-section-3d/ This paper was originally published by Bhaven N. Sampat and Kenneth C. Shadlen in PLoS ONE 13(4): e0194714 under a Creative Commons license. Abstr ...

Diffusion, convergence and influence of pharmaceutical innovations: a comparative study of Chinese and U.S. patents

This article was originally published at https://www.drugpatentwatch.com/blog/diffusion-convergence-and-influence-of-pharmaceutical-innovations-a-comparative-study-of-chinese-and-u-s-patents/ This paper was originally published by Qiaolei Jiang and Chunjuan Luan in Globalization and Health 2018 14 ...

TSI Cannabis Investing Bulletins September 5, 2018

Bulletin 4, Volume 1 TSI Cannabis Investing Bulletins reports on two featured stocks with development projects: one a Canadian pharma stock teaming up with a major grower to develop a new delivery system for medical marijuana, the other a U.S. alcohol giant partnering with a big Canadian grower to ...

Spinoffs, Takeovers and Special Situations Hotline – Friday, August 17, 2018

PERRIGO COMPANY PLC, $72.96, symbol PRGO on New York, is a Dublin-based drug company that sells both generic topical pharmaceutical products as well as over-the-counter store-branded consumer products for coughs, colds, allergies, etc. The over-the-counter products are made for retailers like Walma ...